Market Place
Sourcing Support
Sonex Pharma Evaluates SON-1010 In Sarcoma Phase 1 Study
15 Oct 2025 //
GLOBENEWSWIRE
Sonnet Expands SB101 Trial To Test SON-1010-Trabectedin Combo
21 Jan 2025 //
GLOBENEWSWIRE
Sonnet BioTherapeutics Announces Safety Data from SON-1010 Phase 1
09 Dec 2024 //
GLOBENEWSWIRE
Sonnet BioTherapeutics Publishes SON-1010 IL-12 Fusion Protein Study
04 Dec 2024 //
GLOBENEWSWIRE
Sonnet BioTherapeutics Announces U.S. Patent for IL-18 Variant
06 Nov 2024 //
GLOBENEWSWIRE
Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq
17 Oct 2024 //
GLOBENEWSWIRE
Sonnet Bio Enters into Licensing Agreement with Alkem Laboratories
09 Oct 2024 //
GLOBENEWSWIRE
Sonnet BioTherapeutics To Receive Non-Dilutive Funding
04 Oct 2024 //
GLOBENEWSWIRE
Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split
25 Sep 2024 //
GLOBENEWSWIRE
Sonnet Completes Enrollment In SON-1010 Phase 1 Study
18 Sep 2024 //
GLOBENEWSWIRE
Sonnet Updates SON-1010 Mono/Combo Data, Higher Dose Target
20 May 2024 //
ACCESSWIRE
Sonnet Provides Fiscal Q2 2024, YTD Business And Earnings Update
14 May 2024 //
ACCESSWIRE
Sonnet BioTherapeutics participates in EF Hutton Annual Global Conference
06 May 2024 //
ACCESSWIRE
Sonnet to Present Preclinical Data on SON-080 for (CIPN) the AACR 2024 Meeting
19 Mar 2024 //
ACCESSWIRE
Sonnet Announces Data from the Company’s Phase 1b/2a Clinical Trial of SON-080
11 Mar 2024 //
ACCESSWIRE
Sonnet Announces a Publication Demonstrating Safety of SON-1010
29 Feb 2024 //
ACCESSWIRE
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update
14 Dec 2023 //
ACCESSWIRE
Sonnet Announces Pricing of $4.55 Million Underwritten Public Offering
25 Oct 2023 //
ACCESSWIRE
Sonnet BioTherapeutics Announces Abstract Accepted for Presentation
17 Oct 2023 //
ACCESSWIRE
Sonnet BioTherapeutics Announces 1-for-22 Reverse Stock Split
31 Aug 2023 //
ACCESSWIRE
Sonnet Announces FDA Acceptance of IND for the SB221 Trial of SON-1010
16 Aug 2023 //
ACCESSWIRE
Sonnet BioTherapeutics Provides Fiscal Year 2023 Third Quarter Earnings Update
14 Aug 2023 //
ACCESSWIRE
Sonnet BioTherapeutics to Present at 2023 BTIG Virtual Biotechnology Conference
31 Jul 2023 //
ACCESSWIRE
Sonnet BioTherapeutics Announces $2.25 M Registered Direct Offering
28 Jun 2023 //
ACCESSWIRE
Sonnet Announces Presentations at the 2023 Cytokine-Based Drug Development
23 Jun 2023 //
ACCESSWIRE
Sonnet Announces Regulatory Approval for Initiation of a Trial of SON-1010
20 Jun 2023 //
ACCESSWIRE
Sonnet to Present Data from the SB101 Study with SON-1010 at the AACR
14 Mar 2023 //
ACCESSWIRE
Sonnet Provides Fiscal Year 2023 First Quarter Business and Earnings Update
13 Feb 2023 //
ACCESSWIRE
Sonnet Announces Pricing of $15.0 Million Underwritten Public Offering
08 Feb 2023 //
ACCESSWIRE
Sonnet Announces Data in a Phase 1 Dose-Escalation Trial of SON-1010
19 Jan 2023 //
ACCESSWIRE
